EPS Bio Business Summary

EPS Bio Technology Corp. (4183.TWO) is a Taiwan-based medical device manufacturer specializing in the development and production of blood glucose monitoring (BGM) systems. The company primarily generates revenue through an OEM/ODM business model, providing customized glucose meters and high-margin test strips to international healthcare distributors and private labels, with a significant market presence in Germany and the Middle East. Its product portfolio includes the proprietary EASYMAX and MDT2 BLE brands, as well as advanced wearable diagnostics featuring NFC and Bluetooth connectivity for digital health management. Within the competitive landscape, EPS Bio competes directly with regional peers such as Bionime Corp (4737), Ok Biotech (4155), and Pacific Hospital Supply (4126), positioning itself as a specialized, R&D-focused player in the chronic disease management sector. The company is led by a veteran management team with deep roots in Taiwan’s medical technology ecosystem. Chairman Feng-Lin Guo and Vice Chairman Lien-Fu Liu oversee strategic direction, while CEO Cheng-Hui Cho leads operational execution and international market expansion. Financial oversight is managed by CFO and Deputy General Manager Pai-Hsiung Kuo, a Soochow University alumnus with extensive experience in corporate finance and business management. In August 2024, the company further strengthened its technical leadership by appointing Lin Chih-Heng as Research and Development Officer to spearhead next-generation in-vitro diagnostics. Notable institutional backing includes Zhengji Investment Co., Ltd., which remains a top shareholder and key stakeholder on the board of directors.